Neuprozyme Therapeutics ApS: Financial statements 2022
CVR: 40010106
Source: annual report 2022, Danish Business Authority
01/07/2021 – 30/06/2022
Neuprozyme Therapeutics ApS (CVR 40010106) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 576,182 and a net result of DKK 436,098 compared with DKK -289,040 the year before. That is a decrease of 44.1% compared with the year before. Equity in the 2022 report amounted to DKK 154,016. The solvency ratio was 9.1%.
- Gross Profit
- DKK 576,182
- Profit/Loss
- DKK 436,098
- Equity
- DKK 154,016
- Total Assets
- DKK 1,695,420
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 576K | 436K | 154K | - |
| 2021 | - | 1M | -289K | -282K | - |
| 2020 | - | -39K | -36K | 7K | 0 |
| 2019 | - | -8K | -8K | 43K | - |
| 2018 | - | - | 0 | 50K | - |
Official annual report
Keep an eye on Neuprozyme Therapeutics ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringAbout Neuprozyme Therapeutics ApS
Neuprozyme Therapeutics ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2018. The company is registered under the industry Fremstilling af andre organiske basiskemikalier. The management consists of John Pedersen. The board consists of John Pedersen and Lone Ballegaard Pedersen. The company is owned by LJP HOLDING ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -27,482 and a net result of DKK -25,574 compared with DKK -24,871 the year before. Equity in the 2025 report amounted to DKK 82,360.